<DOC>
	<DOCNO>NCT01021683</DOCNO>
	<brief_summary>The purpose observational study investigate whether sufficient concentration itraconazole influence disappearance fever ( defeverscence ) intravenous ( vein ) itraconazole administer resolve unknown neutropenic fever participant give itraconazole oral solution prophylaxis general treatment condition .</brief_summary>
	<brief_title>The Relationship Defeverscence Itraconazole Plasma Level Study Immunocompromised Participants</brief_title>
	<detailed_description>This prospective ( study follow patient forward time ) , open-label ( people know identity intervention ) , multi-center ( conducted one center ) observational study examine correlation sufficient blood concentration itraconazole disappearance fever ( defeverscence ) itraconazole injection administer resolve unknown neutropenic fever participant give itraconazole oral solution prophylaxis general treatment condition . The recommended dose drug 200 milligram ( mg ) , administer intravenously , twice daily 2 day ( total 4 dos ) 200 mg daily 12 day . After administration total 14 day , itraconazole oral solution 200 mg ( equivalent 20 ml ) twice daily continue total 14 day clinically significant neutropenia resolve .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Immunocompromised participant neutropenic fever treat itraconazole oral solution prophylaxis Female participant postmenopausal receive contraceptive operation refrain sexual relation woman childbearing potential conduct effective method birth control ( oral contraceptive , injection , intrauterine device , double barrier method , contraceptive patch male partner 's sterilization ) participation study Male participant baby within 2 month completion itraconazole therapy Fever due document deepseated fungal infection entry study , document candidemia include Participants kidney function relate abnormality calculate creatinine clearance 30 milliliter per minute ( mL/min ) low Aminotransferase level 5 time higher normal limit total bilirubin level 5 milliliter per deciliter ( mL/dL ) high due hepatic dysfunction Participants dementia ( mental decline ) relate head injury hypoxic brain injury Participants mental illness may interfere cooperation treatment monitor condition clinical study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Hematological neoplasm</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Fever</keyword>
	<keyword>Itraconazole</keyword>
	<keyword>Sporanox</keyword>
	<keyword>Antifungal prophylaxis</keyword>
	<keyword>Defeverscence</keyword>
</DOC>